HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA as Early Warning Biomarkers for COVID-19 Progression and Myocardial Injury.

Abstract
Background: The symptoms of coronavirus disease 2019 (COVID-19) range from moderate to critical conditions, leading to death in some patients, and the early warning indicators of the COVID-19 progression and the occurrence of its serious complications such as myocardial injury are limited. Methods: We carried out a multi-center, prospective cohort study in three hospitals in Wuhan. Genome-wide 5-hydroxymethylcytosine (5hmC) profiles in plasma cell-free DNA (cfDNA) was used to identify risk factors for COVID-19 pneumonia and develop a machine learning model using samples from 53 healthy volunteers, 66 patients with moderate COVID-19, 99 patients with severe COVID-19, and 38 patients with critical COVID-19. Results: Our warning model demonstrated that an area under the curve (AUC) for 5hmC warning moderate patients developed into severe status was 0.81 (95% CI 0.77-0.85) and for severe patients developed into critical status was 0.92 (95% CI 0.89-0.96). We further built a warning model on patients with and without myocardial injury with the AUC of 0.89 (95% CI 0.84-0.95). Conclusion: This is the first study showing the utility of 5hmC as an accurate early warning marker for disease progression and myocardial injury in patients with COVID-19. Our results show that phosphodiesterase 4D and ten-eleven translocation 2 may be important markers in the progression of COVID-19 disease.
AuthorsHang-Yu Chen, Xiao-Xiao Li, Chao Li, Hai-Chuan Zhu, Hong-Yan Hou, Bo Zhang, Li-Ming Cheng, Hui Hu, Zhong-Xin Lu, Jia-Xing Liu, Ze-Ruo Yang, Lei Zhang, Nuo Xu, Long Chen, Chuan He, Chao-Ran Dong, Qing-Gang Ge, Jian Lin
JournalFrontiers in cell and developmental biology (Front Cell Dev Biol) Vol. 9 Pg. 781267 ( 2021) ISSN: 2296-634X [Print] Switzerland
PMID35071229 (Publication Type: Journal Article)
CopyrightCopyright © 2022 Chen, Li, Li, Zhu, Hou, Zhang, Cheng, Hu, Lu, Liu, Yang, Zhang, Xu, Chen, He, Dong, Ge and Lin.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: